{
    "data": [
        {
            "id": "4032184",
            "type": "article",
            "attributes": {
                "publishOn": "2016-12-22T09:12:41-05:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Is A Force For Good - And A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102572",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "182087",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4032184-mylan-is-force-for-good-and-buy"
            }
        },
        {
            "id": "4029193",
            "type": "article",
            "attributes": {
                "publishOn": "2016-12-08T12:25:05-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Opportunity On The Dip",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "181560",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4029193-mylan-opportunity-on-dip"
            }
        },
        {
            "id": "4025432",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-22T09:20:29-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Real Reason Mylan Declined The Senate Judiciary Committee's Invitation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180953",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4025432-real-reason-mylan-declined-senate-judiciary-committees-invitation"
            }
        },
        {
            "id": "4025041",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-21T02:37:41-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Ignore Oral Epinephrine, It Is Not A Threat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180888",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4025041-mylan-ignore-oral-epinephrine-is-not-threat"
            }
        },
        {
            "id": "4022255",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-10T18:05:47-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Has A Clear Path To $60",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57252",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180491",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4022255-mylan-clear-path-to-60"
            }
        },
        {
            "id": "4022003",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-10T08:48:14-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Our Quick Initial Take On Mylan's Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180467",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4022003-quick-initial-take-on-mylans-earnings"
            }
        },
        {
            "id": "4021512",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-09T09:29:52-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Is Now Simply The Best Buy In The Best Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180425",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4021512-mylan-is-now-simply-best-buy-in-best-sector"
            }
        },
        {
            "id": "4021036",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-08T09:19:15-05:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2 Reasons Mylan May Have Bottomed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180384",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4021036-2-reasons-mylan-may-bottomed"
            }
        },
        {
            "id": "4019608",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-04T10:29:33-04:00",
                "isLockedPro": false,
                "commentCount": 47,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Headline Misinterpretation Causes Unprecedented Buying Opportunity, We More Than Tripled Our Position",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180253",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4019608-mylan-headline-misinterpretation-causes-unprecedented-buying-opportunity-tripled-position"
            }
        },
        {
            "id": "4016907",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-30T21:11:24-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Citron Goes Long Mylan, Expect More Notable Investors To Follow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "180028",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4016907-citron-goes-long-mylan-expect-notable-investors-to-follow"
            }
        },
        {
            "id": "4015101",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-26T10:33:15-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Patience Will Pay Off",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "179867",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4015101-mylan-patience-will-pay-off"
            }
        },
        {
            "id": "4013062",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-19T07:58:45-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: EpiPen Classification Continues To Plague",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21950",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4013062-mylan-epipen-classification-continues-to-plague"
            }
        },
        {
            "id": "4012430",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-17T03:32:24-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Now Likely An Acquisition Target With 100% Upside Possible",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "179490",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4012430-mylan-now-likely-acquisition-target-100-percent-upside-possible"
            }
        },
        {
            "id": "4011444",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-11T10:37:24-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Clarifying Confusion Over Mylan's EpiPen Profits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "233032",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4011444-clarifying-confusion-over-mylans-epipen-profits"
            }
        },
        {
            "id": "4011373",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-11T03:02:11-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Should Mylan's Shareholders Hang On Following Government Settlement?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "179309",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4011373-should-mylans-shareholders-hang-on-following-government-settlement"
            }
        },
        {
            "id": "4010926",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-10T12:04:18-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Market Challenge: Mylan A Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80275",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4010926-market-challenge-mylan-buy"
            }
        },
        {
            "id": "4011163",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-10T09:43:15-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Could Now Jump 20% Short Term, 75% Long Term",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "179263",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4011163-mylan-now-jump-20-percent-short-term-75-percent-long-term"
            }
        },
        {
            "id": "4009160",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-29T09:07:00-04:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Would A Generic Version Of EpiPen Affect Its Revenue?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102229",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "178876",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4009160-mylan-generic-version-of-epipen-affect-revenue"
            }
        },
        {
            "id": "4008530",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-26T17:06:38-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "2 Takeaways From The Mylan Congressional EpiPen Hearing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "232944",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4008530-2-takeaways-from-mylan-congressional-epipen-hearing"
            }
        },
        {
            "id": "4007966",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-22T17:42:40-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Where Did All That EpiPen Money Go?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24276",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4007966-where-all-epipen-money-go"
            }
        },
        {
            "id": "4006950",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-19T03:29:24-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: And Like That, The EpiPen Outrage Fades",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "178458",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4006950-mylan-and-like-epipen-outrage-fades"
            }
        },
        {
            "id": "4005470",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-11T12:50:46-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Ditch The Media Narrative And Buy It Before It's Bought Out",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "178221",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4005470-mylan-ditch-media-narrative-and-buy-bought-out"
            }
        },
        {
            "id": "4004894",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-08T08:49:00-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: The Calm Before The Storm",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "232861",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4004894-mylan-calm-storm"
            }
        },
        {
            "id": "4004249",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-06T04:21:19-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Pencil Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78045",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4004249-mylan-pencil-down"
            }
        },
        {
            "id": "4004119",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-05T05:46:59-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Schadenfreude Aside, Mylan Is Now Takeover Bait With A Possible 50% Return",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "66103",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177980",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4004119-schadenfreude-aside-mylan-is-now-takeover-bait-possible-50-percent-return"
            }
        },
        {
            "id": "4004096",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-05T04:02:53-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buying The Most Hated Company In The World",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177973",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4004096-buying-hated-company-in-world"
            }
        },
        {
            "id": "4003451",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-31T17:29:26-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Hillary Clinton Will Now Write Your Prescription - Part 1",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177882",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4003451-mylan-hillary-clinton-will-now-write-your-prescription-part-1"
            }
        },
        {
            "id": "4003373",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-31T13:21:19-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Hillary Clinton Will Now Write Your Prescription - Part 2",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177870",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4003373-mylan-hillary-clinton-will-now-write-your-prescription-part-2"
            }
        },
        {
            "id": "4003231",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-31T07:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan Cuts Price; Trump Hikes Rent (Podcast)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "40141",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4003231-mylan-cuts-price-trump-hikes-rent-podcast"
            }
        },
        {
            "id": "4002738",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-29T07:42:48-04:00",
                "isLockedPro": false,
                "commentCount": 92,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "EpiPen: Facts Vs. Opinion; With Cost-Benefit Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4002738-epipen-facts-vs-opinion-cost-benefit-analysis"
            }
        },
        {
            "id": "4002686",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-29T03:43:41-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Hate The Game, Not The Player? - Mylan Is Out Of Tune Amid An Angry Chorus",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21950",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4002686-hate-game-not-player-mylan-is-out-of-tune-amid-angry-chorus"
            }
        },
        {
            "id": "4002542",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-27T23:44:21-04:00",
                "isLockedPro": false,
                "commentCount": 59,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The EpiPen Lies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "69675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4002542-epipen-lies"
            }
        },
        {
            "id": "4002438",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-26T14:37:07-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Self-Inflicted Wounds Are A Big Problem",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "232779",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4002438-mylan-self-inflicted-wounds-are-big-problem"
            }
        },
        {
            "id": "4002318",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-26T07:51:05-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What's Going On At Mylan?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75715",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4002318-going-on-mylan"
            }
        },
        {
            "id": "4002173",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-25T15:27:00-04:00",
                "isLockedPro": false,
                "commentCount": 310,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Shocked! Mylan, Biotechs Swoon After Hillary's Statement",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177620",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4002173-shocked-mylan-biotechs-swoon-after-hillarys-statement"
            }
        },
        {
            "id": "4002142",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-25T14:15:21-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: Keeping The Faith",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101801",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177615",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4002142-mylan-keeping-faith"
            }
        },
        {
            "id": "4001978",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-25T03:58:48-04:00",
                "isLockedPro": false,
                "commentCount": 49,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: A Shameful Cash Grab",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74295",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4001978-mylan-shameful-cash-grab"
            }
        },
        {
            "id": "3974185",
            "type": "article",
            "attributes": {
                "publishOn": "2016-05-11T14:35:59-04:00",
                "isLockedPro": false,
                "commentCount": 63,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Generic Stocks Down; Are They Good Buys? Focus On Teva",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "173202",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/3974185-generic-stocks-down-are-good-buys-focus-on-teva"
            }
        },
        {
            "id": "3973530",
            "type": "article",
            "attributes": {
                "publishOn": "2016-05-10T10:11:39-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4 Microcaps With Major Catalysts",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31691",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3973530-4-microcaps-major-catalysts"
            }
        },
        {
            "id": "3972750",
            "type": "article",
            "attributes": {
                "publishOn": "2016-05-08T05:17:20-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cyclical Strategy Says Buy Mylan",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "172997",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3972750-cyclical-strategy-says-buy-mylan"
            }
        },
        {
            "id": "3903546",
            "type": "article",
            "attributes": {
                "publishOn": "2016-02-17T14:55:48-05:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan: What Is $6 EPS In 2017 Worth?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "169633",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3903546-mylan-what-is-6-eps-in-2017-worth"
            }
        },
        {
            "id": "3897076",
            "type": "article",
            "attributes": {
                "publishOn": "2016-02-16T01:51:22-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Mylan - Positive Investment Alert",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "34431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "169538",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3897076-mylan-positive-investment-alert"
            }
        },
        {
            "id": "3892436",
            "type": "article",
            "attributes": {
                "publishOn": "2016-02-12T13:10:50-05:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Acquisition Rocks Mylan: Stock Half Of Teva's Previous Buyout Offer",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "169457",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "606785",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3892436-acquisition-rocks-mylan-stock-half-of-tevas-previous-buyout-offer"
            }
        }
    ]
}